STAT
JANUARY 10, 2024
This latest revision, known as the DSM-5-TR, was prepared between 2016 and 2019, and published in 2022. The researchers found that, of the 55 physicians with ties to a pharmaceutical company, 91% accepted food and beverages, and 69% received compensation for travel and consulting, according to the analysis published in the BMJ.
STAT
OCTOBER 25, 2023
Oncologists were more likely to provide low-value cancer care after receiving money from pharmaceutical companies, and the findings raise questions about the extent to which industry influence may have led to patient harm, according to a new study. Continue to STAT+ to read the full story…
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
DECEMBER 7, 2023
In 1997, Celgene obtained a key patent for what would become a blockbuster blood cancer treatment, giving it a monopoly until 2019. But like any pharmaceutical company with an eye toward the future, Celgene continued to seek other ways to wring profits from its development work.
LifeProNow
DECEMBER 22, 2023
Pharmasol is under contract with multiple pharmaceutical companies. The most recent inspection of the company’s facilities in 2022 found the majority of the inspectional observations repeated those found in past FDA inspections and detailed in a 2019 warning letter.
Express Pharma
MARCH 31, 2024
In recent years, the Asia-Pacific (APAC) market has emerged as a hub for pharmaceutical development and investment, attracting attention from both local and global players. Kancharla adds, “Of the 360 deals for unique therapy areas, 69 deals** are solely concerned with pipeline molecules, while 32 deals** are all about marketed drugs.
Pharmaceutical Technology
MAY 10, 2023
This marks a significant development in a tumultuous dispute between the pharmaceutical company and the US government. In November 2019, the government sued Gilead over the company’s alleged patent infringement of the two PrEP drugs Descovy and Truvada. Gilead markets both Truvada and its successor Descovy.
Express Pharma
MARCH 18, 2023
ft between 2019-22. LS companies largely preferred Bangalore, followed by Delhi-NCR and Hyderabad for office space take-up in India during the same period. About 57 per cent of the space take-up by LS firms during 2019-22 was led by business expansions with Bangalore, Hyderabad and Delhi as preferred cities. million sq.
Expert insights. Personalized for you.
352 
Let's personalize your content